

Contents

CHAPTER 1

Historical Perspective and Introduction to the Endothelin Family of Peptides

T. MASAKI. With 1 Figure	1
References	7

CHAPTER 2

Sarafotoxins and Their Relationship to the Endothelin Family of Peptides

M. SOKOLOVSKY and Z. SHRAGA-LEVINE	11
A. Introduction	11
B. Structure	12
C. Organization of SRTX cDNA	13
D. Biosynthesis and Degradation	14
E. Receptors	15
I. Binding	15
II. ET _B Receptors	17
III. ET _A Receptors	19
IV. Atypical Receptors	20
F. Differences in Sensitivities to Antagonists	21
G. Similar and Opposing Responses Mediated by ETs/SRTXs	23
H. Signaling Differences Between ET and SRTX	26
I. Conclusions	28
References	29

CHAPTER 3

Identity of Endothelin-Converting Enzyme and Other Targets for the Therapeutic Regulation of Endothelin Biosynthesis

R. CORDER. With 9 Figures	35
A. Biosynthesis of the Endothelins	35

I. Introduction	35
II. Tissue Expression and Localisation	35
III. Regulation of Prepro-ET-1 Expression	37
1. Basal Synthesis	37
2. Ca ²⁺ and Intracellular pH	38
3. Protein Kinase C	38
4. Cytokines	39
5. Thrombin	40
6. Stretch	40
IV. Physiological Functions of ET-1 Biosynthesis	41
1. Role of ET-1 in Development	41
2. ET-1 and Vascular Homeostasis	41
B. Inhibition of ET-1 Synthesis vs Endothelin	
Receptor Antagonists	42
I. Lung	42
1. Pulmonary Hypertension	42
2. Airways Disease	43
II. Atherosclerosis	43
III. Renal Failure	44
C. Endothelin-Converting Enzyme	45
I. Background to Endothelin-Converting Enzyme	45
II. Evidence of a Secondary Structure for Big ET-1	47
III. Molecular Modelling of Big ET-1	48
IV. Endothelin-Converting Enzyme-1	50
1. Purification and Cloning of ECE-1	50
2. Expression and Localisation of ECE-1	51
3. Implications from ECE-1 Gene Deletion Studies	53
V. The Search for the Physiologically Relevant ECE	54
D. Alternative Strategies for Inhibiting ET-1 Synthesis	56
I. Inhibition of Intracellular Signalling Mechanisms	57
II. Anti-Inflammatory Mediators which Suppress	
ET-1 Synthesis	58
E. Summary	58
List of Abbreviations	58
References	59

CHAPTER 4

Endothelin Receptors

P.J. HENRY and R.G. GOLDIE	69
A. Introduction	69
B. Pharmacological Classification of ET Receptors	69
I. General	69

II. ET _A and ET _B Receptor-Selective Agonists and Antagonists	70
III. Characterization of ET _A and ET _B Receptor Populations	71
C. Molecular Biology of ET Receptors	73
I. Cloning of ET Receptor Genes	73
II. Mutations of ET Receptor Genes	74
D. Subclassification of ET _A and ET _B Receptors	75
I. ET _A Receptor Subtypes	75
II. ET _B Receptor Subtypes	76
III. ET _C and Other Putative Subtypes	78
IV. Splice Variants of ET Receptors	79
E. ET Receptor Structure.....	80
I. Structure	80
II. Post-Translational Modification of ET Receptors	81
1. Glycosylation	81
2. Palmitoylation	81
III. Binding Characteristics of ET Receptors	82
1. Differences Between Membranes and Intact Cells	85
F. ET Receptor Coupling.....	85
G. Alterations in ET Receptor Expression and Density	86
I. Desensitization and Internalization	86
II. Drugs	88
1. Glucocorticoids	88
2. Cyclosporine	88
3. Phosphoramidon	89
III. Cytokines and Other Peptides	89
IV. Cell and Tissue Culture	90
V. Development.....	91
VI. Pregnancy/Menstrual Cycle	92
VII. Disease.....	92
H. Summary	98
References	99

CHAPTER 5

Cell Signaling by Endothelin Peptides

M.S. SIMONSON. With 3 Figures	115
A. Introduction and Overview	115
B. Contractile Signaling by ET-1	115
I. Activation of Phospholipase C by Endothelin-1	115
II. Ca ²⁺ Signaling and ET-1-Induced Contraction	116
III. Ca ²⁺ Channels and ET-1	117
IV. Unresolved Issues in ET-1 Ca ²⁺ Signaling	119

V. PKC and ET-1-Induced Contraction	119
C. Genomic Signaling by ET: Cell Growth and Development.	120
I. Mitogenic Signaling by ET	121
1. ET-1 and MAPK Cascades	123
2. ET and Non-Receptor Protein Tyrosine Kinases in Mitogenic Signaling	124
3. ET and Survival, Anti-Apoptotic Signaling	129
II. ET Post-Receptor Signals in Development and Differentiation	130
D. Summary and Perspective	132
References	133

CHAPTER 6

Lessons from Gene Deletion of Endothelin Systems

H. KURIHARA, Y. KURIHARA and Y. YAZAKI. With 1 Figure	141
A. Introduction	141
B. Developmental Defects in Endothelin-Knockout Mice	141
I. Gene Knockout of ET-1/ET-A Receptor Pathway	141
II. Gene Knockout of ET-3/ET-B Receptor Pathway	142
III. Gene Knockout of Endothelin-Converting Enzyme	143
C. Neural Crest and the Endothelin System	143
I. Outline of Neural Crest Development	143
II. Developmental Expression of the ET System	145
III. Involvement of the ET System in Neural Crest Development	145
D. Endothelin-Knockout Mice and Human Diseases	147
I. ET-3/ET-B Receptor Knockout Mice and Hirschsprung's Disease	147
II. ET-1/ET-A Receptor Knockout Mice and Craniofacial/Cardiovascular Disease	149
E. Perspectives	149
References	150

CHAPTER 7

Endothelin-Converting Enzyme Inhibitors and their Effects

B. BATTISTINI and A.Y. JENG. With 6 Figures	155
A. Introduction	155
I. Mature ET Peptides and their Precursors	155
II. ECE: Cloning, Classification, and Cellular Localization	157
III. Alternative Pathways for ET Production and Perspectives Provided by Gene-Targeting Studies	160

1. Aspartyl Proteases	160
2. Thiol (Cysteine) Proteases	161
3. Serine Proteases	162
4. Gene Targeting	162
IV. Modulation of ECE Expression and Activity	163
V. ECE: Substrate Specificity and pH Dependence	163
B. Development of ECE Inhibitors: Chemical Identity, Selectivity, Potency, and Oral Bioavailability	164
I. Chemical Identities of ECE Inhibitors	164
II. Non-Specific ECE Inhibitors: Metal Chelators	171
III. Non-Selective Dual NEP/ECE Inhibitors	173
1. More Potent Against NEP	173
a) Phosphoramidates	173
b) Aminophosphonic Acids	181
c) Carboxylic Acids	181
d) Sulfhydryl-Containing Compounds	181
2. More Potent Against ECE	184
a) Phosphonamides	184
b) Aminophosphonic Acids	184
IV. Non-Selective Triple ACE/NEP/ECE Inhibitors	184
1. Phosphinic Acids	184
2. Phosphonamides	184
3. Aminophosphonic Acid	185
4. Other Compounds	185
V. Selective ECE Inhibitors	185
1. Peptidic Compounds	185
2. Non-Peptidic Compounds from Natural Products	185
3. Other Non-Peptidic Compounds	186
VI. Other Compounds Presenting Some ECE Inhibitory Activities	186
C. Effects of Protease Inhibitors, Chelating Agents and Metal Ions on ECE Activities in Cultured Cells, Isolated Tissues, Perfused Organs, and In Vivo	187
I. In Cultured Cells	187
1. In Endothelial Cells	187
2. In Airway Epithelial Cells	188
3. In Other Types of Cells	188
II. In Isolated Vascular and Non-Vascular Preparations	188
1. Vascular Preparations	188
2. Non-Vascular Preparations	188
III. In Isolated and Perfused Organs	189
IV. In Semi-Purified and Purified Preparations	189
V. In Vivo Studies	189
D. Effect of ECE Inhibitors in Various Pre-Clinical Animal Disease Models and in Clinical Studies	190

I. Cerebral Vasospasm Following Subarachnoid Hemorrhage	191
II. Conditions Associated with Vascular Remodeling	191
1. Hypertension	191
2. Congestive Heart Failure	191
3. Post-Angioplastic Restenosis	192
III. Renal Failure	192
IV. Pulmonary Vascular Diseases	192
V. Pulmonary Respiratory Diseases	193
E. Conclusions and Perspectives	193
References	196

CHAPTER 8

Endothelin Converting Enzymes and Endothelin Receptor Localisation in Human Tissues

A.P. DAVENPORT and F.D. RUSSELL. With 6 Figures.....	209
A. Introduction	209
B. Endothelin Converting Enzymes	209
I. ECE-1	209
1. Localisation of mRNA Encoding Isoforms of ECE-1	210
2. Localisation of ECE-1 Using Immunocytochemistry	210
3. Quantification of ECE-1 Isoforms	210
II. ECE-2	211
C. ECE and ET Receptor Sub-Types in the Peripheral Vasculature	211
I. Ultrastructural Localisation of ECE-1 in Endothelial Cells	211
II. Evidence for Smooth Muscle Cell ECE and Upregulation in Cardiovascular Disease	213
III. ECE-2	216
IV. ET Receptor Sub-Types	218
D. ECE and ET Receptor Sub-Types in Organ Systems	220
I. Heart	220
II. Lungs	221
III. Adrenal Gland	222
IV. Kidney	223
V. Central Nervous System	225
1. Cerebral Vasculature	225
2. Neurones	227
3. Astrocytes	227
4. Neural Receptors	228
E. Conclusions	228

List of Abbreviations	229
References	229

CHAPTER 9

Endothelin Receptor Antagonists

J.D. ELLIOTT and J.-N. XIANG. With 26 Figures	239
A. Peptide Endothelin Receptor Antagonists	239
I. ET _A Selective Antagonists	239
II. ET _B Selective Antagonists	242
III. ET _A /ET _B Balanced Antagonists	244
B. Non-Peptide Endothelin Receptor Antagonists	245
I. ET _A /ET _B Balanced Antagonists	245
II. ET _A Selective Antagonists	252
III. ET _B Selective Antagonists	264
References	265

CHAPTER 10

Toxicology of Endothelin Antagonists

S.J. MORGAN, P.K. CUSICK, and B.A. TRELA	271
A. Introduction	271
B. Cardiovascular System	271
C. Teratology	272
I. ET _A Receptor	272
II. ET _B Receptor	273
D. Clinical Trials	274
References	274

CHAPTER 11

Endothelins and the Release of Autacoids

P. D'ORLÉANS-JUSTE, G. BKAILY, M. DUVAL, J. LABONTÉ, M. PLANTE, G. COURNOYER, and N. BERTHIAUME. With 5 Figures	277
A. Introduction	277
B. Endothelin-Induced Release of Endothelial-Derived Factors	279
I. Nitric Oxide	279
II. Eicosanoids	279
1. Receptors Involved in the Release of Eicosanoids	280
III. Cross-Talk Between the Endothelin, Nitric Oxide and Arachidonic Acid Pathways	282
IV. Intracellular Mechanisms Involved in the Nitric Oxide or PGI ₂ -Induced Downregulation of ET-1 Production	283

V. ET-1-Induced Release of Cytokines	284
C. Autacoid Mediators Generated by Endothelin-1 in Non-Vascular Cells	285
D. Endothelin-Converting Enzyme-Dependent Release of Modulators	287
I. Eicosanoids	287
II. Big-Endothelins and NO	289
E. Modulator-Releasing Properties of Endothelins in Mice	291
I. Nitric Oxide	291
II. Eicosanoids	291
F. Conclusion	293
References	294

CHAPTER 12

The Roles of Endothelins in Proliferation, Apoptosis, and Angiogenesis

J.R. WU-WONG and T.J. OPGENORTH. With 5 Figures	299
A. Introduction	299
B. The Role of Endothelins in Cell Proliferation	300
I. The Mitogenic Effect of ETs	300
II. The Effects of ET-1 on the Migration and Proliferation of Endothelial Cells	303
III. The Anti-Proliferative Effect of ETs	306
C. The Role of Endothelin in Apoptosis	307
D. The Role of Endothelin in Angiogenesis	310
I. Is ET-1 an Angiogenic Factor?	310
II. Is ET-1 Found in Diseases with Angiogenesis?	311
III. Interaction Between ETs and Angiogenic Factors	312
E. Conclusion	314
List of Abbreviations	316
References	316

CHAPTER 13

The Involvement of Endothelins in Cerebral Vasospasm and Stroke

O. TOUZANI and J. McCULLOCH. With 7 Figures	323
A. Introduction	323
B. Endothelins and Endothelin Receptors in the Brain and Cerebral Circulation	324
I. Endothelins in the Brain and Cerebral Circulation	324
II. Endothelin Receptors in the Brain and Cerebral Circulation	324

III. Function of Endothelins in the Brain	325
IV. Endothelins and the Cerebral Circulation	326
1. ET _A Receptor-Mediated Effects	326
2. ET _B Receptor-Mediated Effects	327
3. Role of Endothelins in the Regulation of Cerebrovascular Tone	329
C. Pathophysiological Role of Endothelins in the Cerebral Circulation	330
I. Subarachnoid Haemorrhage	330
1. Cerebrovascular Reactivity to Endothelins	331
2. Levels of Endothelins	332
3. Treatment with Endothelin Receptor Antagonists	334
II. Cerebral Ischaemia	340
1. Clinical Observations in Man	341
2. Induced Cerebral Ischaemia in Animals	342
a) Global Cerebral Ischaemia	342
b) Focal Cerebral Ischaemia	343
D. Concluding Remarks	346
References	346

CHAPTER 14

Involvement of the Endothelins in Airway Reactivity and Disease

R.G. GOLDIE and P.J. HENRY. With 1 Figure	357
A. Introduction	357
B. The Endothelin System	358
I. Is There a Link to Asthma?	358
II. ET Structure, Synthesis and Degradation	358
1. Structure	358
2. Synthesis	358
3. Degradation	359
C. ET Receptors	360
D. ET and the Major Pathologies in Respiratory Diseases	360
I. Asthma	360
II. Allergic Rhinitis	361
III. Adult Respiratory Distress Syndrome (ARDS)	361
IV. Cryptogenic Fibrosing Alveolitis (CFA)	361
V. Pulmonary Fibrosis	362
VI. Pulmonary Tumours	362
E. ET-1 and the Standard Criteria for Mediator Status in Asthma	362
I. Synthesis, Release and Degradation of the ETs in the Lung	363
1. Synthesis	363

2. Release	363
3. Degradation	363
II. ET Receptor Distribution	364
1. Airway Smooth Muscle	364
2. Other Sites	364
III. ET Receptor-Mediated Responses Relevant to Asthma	365
1. Altered Bronchial Tone	365
a) Direct Airway Smooth Muscle Contraction	366
b) Modulation of Neurotransmission	366
c) Bronchoconstriction In Vivo	367
2. Mitogenesis	368
a) Fibroblasts	368
b) Airway Smooth Muscle	369
c) Mucous Glands	369
3. Secretion of Mucus	370
4. Altered Microvascular Permeability	370
5. ET-1 as a Pro-Inflammatory Mediator	370
a) ET-1-Induced Pro-Inflammatory Mediator Release	371
b) ET-1-Induced Inflammatory Cell Chemotaxis	371
c) Some Evidence Against a Major Pro-Inflammatory Role for ET-1 in the Airways	371
IV. Airway Inflammation, Increased ET Levels and Asthma ...	372
1. Evidence from Models In Vitro	372
2. Evidence from Animal Models Ex Vivo or In Vitro	372
3. Asthma-Associated Airway Inflammation and ET Levels	373
4. Respiratory Tract Viral Infection, Asthma and ETs	374
5. ET Levels and Asthma Symptoms	374
F. Conclusions.....	375
References	375

CHAPTER 15

Endothelin-1 and Pulmonary Hypertension

D.J. STEWART and Y.D. ZHAO. With 3 Figures	389
A. Mechanisms of Pulmonary Hypertension	389
B. Endothelial Dysfunction and Pulmonary Hypertension	390
C. The Search for a "Vasoconstrictor Factor" in Pulmonary Hypertension	390
D. ET-1 Homeostasis in the Pulmonary Vasculature in Health and Disease	393
E. Role of ET Antagonists in Pulmonary Hypertension	397
References	400

Vascular and Cardiac Effects of Endothelin

S.A. DOUGLAS and E.H. OHLSTEIN	405
A. Endothelin-Induced Vascular Smooth Muscle Contraction	405
B. Modulatory Role of the Endothelium on the Contractile Actions of the Endothelin Isopeptides	406
C. Multiple Receptor Subtypes Mediating the Vascular Actions of Endothelin-1	406
D. Cardiac Actions of Endothelin-1	408
E. Integrated Cardiovascular Actions of Endothelin-1	409
F. Functional Genomics	412
I. Endothelin Isopeptides	412
II. ET _A and ET _B Receptor	413
III. Endothelin Converting Enzyme	413
G. Hemodynamic Actions of ET-1 in Man	413
I. Endothelin Isopeptide Administration	414
II. Endothelin Receptor Antagonism	414
H. Endothelin-1 and the Central Control of Cardiovascular Function	415
I. Endothelin-1 and “Endothelium-Derived Contracting Factor (EDCF)”	416
J. Endothelin-1 and the Control of Smooth Muscle and Myocyte Structure	416
K. Hemostatic Actions of Endothelin-1	419
L. Endothelin and the Pathogenesis of Cardiovascular Dysfunction	419
I. Congestive Heart Failure	419
II. Hypertension	422
III. Atherosclerosis and Vascular Restenosis	425
IV. Myocardial Ischemia	427
V. Cerebral Vasospasm, Stroke, and Subarachnoid Hemorrhage	427
VI. Diabetes	428
VII. Endotoxic Shock	428
VIII. Migraine	429
IX. Reynaud’s Phenomenon	429
M. Pharmacological Profile for the Treatment of Cardiovascular Disease	429
N. Summary	430
References	430

Endothelins Within the Liver and the Gastrointestinal System

B. BATTISTINI	453
A. Introduction: The ET System in the Liver and the GI Tract	453
I. ETs and ET Receptors	453
II. In Situ and/or Immunocytochemical Distribution	454
III. Production, Release and Tissue Levels of ETs	454
IV. Metabolism	455
B. The Pharmacology of ETs in the Hepatopancreatic System	456
I. ET-Induced Responses in the Liver and Pancreas	456
II. ET-Induced Responses in Hepatic and Pancreatic Cells	456
C. Responses of Isolated Smooth Muscle Preparations Related to the GI System	457
I. The Esophagus	457
II. The Stomach and Gastric Cells	458
1. ET-Induced Vascular Response of the Stomach	458
2. ET-Induced Contraction of the Fundus	458
3. ET-Induced Effects in Gastric Cells	459
III. The Gallbladder	459
IV. The Duodenum	460
V. The Jejunum	461
VI. The Ileum	461
VII. The Colon	462
D. Possible Roles of ETs in Gastrointestinal Diseases and Clinical Relevance	463
I. Animal Models of GI Disorders: Modulation of the ET System and Treatment with ET Antibodies, ECE Inhibitors, or ET Receptor Antagonists	463
1. Portal Hypertension	463
2. Gastric/Duodenal Mucosal Injury and Ulceration	463
3. Chronic or Acute Pancreatitis	465
4. Inflammatory Bowel Disease	466
5. Intestinal Mucosal Acidosis	466
II. Human Subjects and Patients	467
1. Peptic Ulcer	467
2. Chronic Pancreatitis	467
3. Inflammatory Bowel Diseases: Crohn's Disease and Ulcerative Colitis	467
E. Discussion and Conclusions	468
References	468

CHAPTER 18

Endothelin and the Kidney

D.M. POLLOCK	477
A. Introduction	477
B. Localization of ET-1, ECE, and Endothelin Receptors in the Kidney	477
C. Hemodynamic Effects of Exogenous ET-1 in the Kidney	479
D. Tubular Actions of Endothelin	481
E. Role of Endothelin in Control of Excretory Function	482
F. Interaction Between Endothelial Factors in the Kidney	484
G. Role of Renal ET-1 in Hypertension	485
H. Role of ET-1 in Acute Renal Failure	487
I. Role of ET-1 in Chronic Renal Failure	490
J. Conclusion	492
References	492

CHAPTER 19

Endothelin Ligands and their Experimental Effects Within the Human Circulation

S.J. LESLIE and D.J. WEBB	503
A. Introduction	503
B. Research Tools Used in Human Subjects	503
I. Local Study Techniques	503
II. Systemic Study Techniques	504
C. Endothelin Ligands Used in Human Studies	505
D. Endothelin Ligands and their Effects in Healthy Volunteers	506
I. Local Activation of the Endothelin System in Healthy Volunteers	506
1. Resistance Vessels	506
2. Capacitance Vessels	507
3. Microcirculation	507
II. Local Inhibition of the Endothelin System in Healthy Volunteers	508
1. Resistance Vessels	508
2. Microcirculation	508
III. Systemic Activation of the Endothelin System in Healthy Volunteers	509
1. Cardiovascular Effects	509
2. Renovascular Effects	509
IV. Systemic Inhibition of the Endothelin System in Healthy Volunteers	510
1. Cardiovascular Effects	510

a) Non-Selective Inhibition	510
b) Selective Inhibition	510
2. Renovascular Effects	511
E. Endothelin Ligands and their Effects in Patients	511
I. Heart Disease	511
1. Congestive Heart Failure	511
2. Coronary Artery Disease (CAD)	513
3. Hypertension	513
II. Renal Disease	514
1. Chronic Renal Failure	514
2. Hepatorenal Failure	514
3. Contrast Nephropathy	515
F. Conclusion	515
References	515
Subject Index.....	521